Eric Fortin

Eric Fortin

Auto-generated profile, based on publicly available information

Eric Fortin

Eric Fortin, MD, University of Montreal Ophthalmology Clinical Center at Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Ophthalmology
Verified
Journal Article
Open access
ESEric B. Suhler
Eric B. Suhler
GJGlenn J. Jaffe
Glenn J. Jaffe
EFEric Fortin
Eric Fortin
LLLyndell Lim
Lyndell Lim
PMPauline T. Merrill
Pauline T. Merrill
JRJames T. Rosenbaum
James T. Rosenbaum
To evaluate long-term efficacy and safety of extended treatment with adalimumab in patients with noninfectious intermediate, posterior, or panuveitis. Open-label, multicenter, phase 3 extension study (VISUAL III). Adults who had completed a randomized, placebo-controlled phase 3 parent trial (VISUAL I or II) without treatment failure (inactive uveitis) or who discontinued the study after meeting treatment failure criteria (active uveitis). Patients received subcutaneous adalimumab 40 mg every other week. Data were collected for ≤ 362 weeks. Adverse events (AEs) were recorded until 70 days after the last dose. Long-term safety and quiescence; other efficacy variables included inflammatory lesions, anterior chamber cell and vitreous haze grade, macular edema, visual acuity, and dose of uveitis-related systemic corticosteroids. At study entry, 67% of patients (283/424) showed active uveitis and 33% (141/424) showed inactive uveitis; 60 patients subsequently met exclusion criteria, and 364 were included in the intention-to-treat analysis. Efficacy variables were analyzed through week 150, when approximately 50% of patients (214/424) remained in the study. Patients showing quiescence increased from 34% (122/364) at week 0 to 85% (153/180) at week 150. Corticosteroid-free quiescence was achieved by 54% (66/123) and 89% (51/57) of patients with active or inactive uveitis at study entry. Mean daily dose of systemic corticosteroids was reduced from 9.4 ± 17.1 mg/day at week 0 (n = 359) to 1.5 ± 3.9 mg/day at week 150 (n = 181). The percentage of patients who achieved other efficacy variables increased over time for those with active uveitis at study entry and was maintained for those with inactive uveitis. The most frequently reported treatment-emergent AEs of special interest were infections (n = 275; 79 events/100 patient-years [PY]); AEs and serious AEs occurred at a rate of 396 events/100 PY and 15 events/100 PY, respectively. Long-term treatment with adalimumab led to quiescence and reduced corticosteroid use for patients who entered VISUAL III with active uveitis and led to maintenance of quiescence for those with inactive uveitis. AEs were comparable with those reported in the parent trials and consistent with the known safety profile of adalimumab.

15 October 2022 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
RBRoberta Berard
Roberta Berard
HNHon Yan Ng
Hon Yan Ng
AHAndrea Human
Andrea Human
DPDavid Piskin
David Piskin
MDMuhammed Dhalla
Muhammed Dhalla
DLDeborah M. Levy
Deborah M. Levy
Objective To develop Canadian recommendations for the screening, monitoring and treatment of uveitis associated with Juvenile Idiopathic Arthritis (JIA). Methods Recommendations were developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE)-Adolopment approach. A working group of 14 pediatric rheumatologists, 6 ophthalmologists, 2 methodologists and 3 caregiver/patient representatives reviewed recent American College of Rheumatology (ACR)/Arthritis Foundation (AF) recommendations and worked in pairs to develop evidence-to-decision (EtD) tables. A survey to assess agreement and recommendations requiring group discussion was completed. EtD tables were presented, discussed, and voted upon at a virtual meeting, to produce the final recommendations. A health equity framework was applied to all aspects of the adolopment process including EtD tables, survey responses, and virtual meeting discussion. Results The survey identified that 7 of the nineteen recommendations required rigorous discussion. Seventy-five percent of working group members attended the virtual meeting to discuss controversial topics as they pertained to the Canadian environment, including timing to first eye exam, frequency of screening, escalation criteria for systemic and biologic therapy, and the role of non-biologic therapies. Equity issues related to access to care and advanced therapeutics across Canadian provinces and territories were highlighted. Following the virtual meeting, 5 recommendations were adapted, 2 recommendations were removed, and 1 was developed de novo. Conclusion Recommendations for JIA-associated uveitis were adapted to the Canadian context by a Working Group of pediatric rheumatologists, ophthalmologists with expertise in the management of uveitis and parent/patient input utilizing lenses for cost, equity, and access.

1 July 2023 in The Journal of Rheumatology
Verified
Journal Article
Open access
PDF file
CGChloe Gottlieb
Chloe Gottlieb
RBRoberta Berard
Roberta Berard
DLDeborah M. Levy
Deborah M. Levy
EFEric Fortin
Eric Fortin
We thank the author for their reply1 and appreciate the approach of having clear terminology and standard definitions within clinical practice guidelines or recommendations, that are applicable across specialist groups. A definition of controlled anterior uveitis or quiescent disease is important for treatment decisions, particularly when classifying a patient9s disease as failing current therapy and making decisions for escalating therapy.